Providence, RI, July 2, 2013 – (eTeligis via Accesswire) – Mnemosyne Pharmaceuticals, Inc., an emerging biotechnology company focused on the discovery and development of small molecule drugs ...

Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs PROVIDENCE, RI, Feb 16, 2012 (MARKETWIRE via COMTEX) -- Mnemosyne Pharmaceuticals, Inc., an ...

Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A financing to advance its work on a class of molecules known as ...

Mnemosyne Pharmaceuticals Inc. has landed $5.4 million in a Series A funding round, led by Access BridgeGap Ventures of Cambridge, with participation from Slater Technology Fund, the official ...

Mnemosyne Pharmaceuticals Inc. has raised a $5.4 million Series A round to continue research on an oral drug with potential to treat cognitive symptoms of diseases such as schizophrenia and ...